Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Val J Gebski

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.
Clinical Colorectal Cancer|November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM StudyJeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyEva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyNiall C Tebbutt, Kate Wilson, Val J Gebski, et al.
Clinical Colorectal Cancer|November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM StudyJeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM StudyEva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
Pageof 5